Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceuticals), KP104 (Kira Pharmaceuticals), and others...
Covered in this story
What has happened since
- Regeneron Pharmaceuticals is up 0.4% since this was published, 33 days ago.
- Novo Nordisk is down 6.5% since this was published, 33 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Regeneron Pharmaceuticals
- Jefferies: $735 → $930 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $REGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Regeneron Pharmaceuticals →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.